Publications

    1. Reducing Endogenous a-Synuclein Mitigates the Degeneration of Selective Neuronal Populations in an Alzheimer's Disease Transgenic Mouse Model. Spencer B, Desplats PA, Overk CR, Valera-Martin E, Rissman RA, Wu C, Mante M, Adame A, Florio J, Rockenstein E, Masliah E. J Neurosci. 2016 Jul 27;36(30):7971-84. PMID: 27466341
    2. a-Synuclein interferes with the ESCRT-III complex contributing to the pathogenesis of Lewy body disease. Spencer B, Kim C, Gonzalez T, Bisquertt A, Patrick C, Rockenstein E, Adame A, Lee SJ, Desplats P, Masliah E. Hum Mol Genet. 2016 Mar 15;25(6):1100-15. PMID: 26740557
    3. Neuropeptide treatment with Cerebrolysin improves the survival of neural stem cell grafts in an APP transgenic model of Alzheimer disease. Rockenstein E, Desplats P, Ubhi K, Mante M, Florio J, Adame A, Winter S, Brandstaetter H, Meier D, Masliah E. Stem Cell Res. 2015 Jul;15(1):54-67. PMID: 26209890
    4. Perinatal programming of neurodevelopment: epigenetic mechanisms and the prenatal shaping of the brain. Desplats PA. Adv Neurobiol. 2015;10:335-61. PMID: 25287548
    5. Epigenetic alterations in the brain associated with HIV-1 infection and methamphetamine dependence. Desplats P, Dumaop W, Cronin P, Gianella S, Woods S, Letendre S, Smith D, Masliah E, Grant I. PLoS One. 2014 Jul 23;9(7):e102555. PMID: 25054922
    6. ESCRT-mediated uptake and degradation of brain-targeted a-synuclein single chain antibody attenuates neuronal degeneration in vivo. Spencer B, Emadi S, Desplats P, Eleuteri S, Michael S, Kosberg K, Shen J, Rockenstein E, Patrick C, Adame A, Gonzalez T, Sierks M, Masliah E. Mol Ther. 2014 Oct;22(10):1753-67. PMID: 25008355
    7. Hippocampal neuronal cells that accumulate a-synuclein fragments are more vulnerable to Aß oligomer toxicity via mGluR5--implications for dementia with Lewy bodies. Overk CR, Cartier A, Shaked G, Rockenstein E, Ubhi K, Spencer B, Price DL, Patrick C, Desplats P, Masliah E. Mol Neurodegener. 2014 May 19;9:18. PMID: 24885390
    8. A neuroprotective brain-penetrating endopeptidase fusion protein ameliorates Alzheimer disease pathology and restores neurogenesis. Spencer B, Verma I, Desplats P, Morvinski D, Rockenstein E, Adame A, Masliah E. J Biol Chem. 2014 Jun 20;289(25):17917-31. PMID: 24825898
    9. Distinctive patterns of DNA methylation associated with Parkinson disease: identification of concordant epigenetic changes in brain and peripheral blood leukocytes. Masliah E, Dumaop W, Galasko D, Desplats P. Epigenetics. 2013 Oct;8(10):1030-8. PMID: 23907097
    10. TOM40 mediates mitochondrial dysfunction induced by a-synuclein accumulation in Parkinson's disease. Bender A, Desplats P, Spencer B, Rockenstein E, Adame A, Elstner M, Laub C, Mueller S, Koob AO, Mante M, Pham E, Klopstock T, Masliah E. PLoS One. 2013 Apr 23;8(4):e62277. PMID: 23626796
    11. Molecular and pathologic insights from latent HIV-1 infection in the human brain. Desplats P, Dumaop W, Smith D, Adame A, Everall I, Letendre S, Ellis R, Cherner M, Grant I, Masliah E. Neurology. 2013 Apr 9;80(15):1415-23. PMID: 23486877
    12. Combined exposure to Maneb and Paraquat alters transcriptional regulation of neurogenesis-related genes in mice models of Parkinson's disease. Desplats P, Patel P, Kosberg K, Mante M, Patrick C, Rockenstein E, Fujita M, Hashimoto M, Masliah E. Mol Neurodegener. 2012 Sep 28;7:49. PMID: 23017109
    13. Antibody-aided clearance of extracellular a-synuclein prevents cell-to-cell aggregate transmission. Bae EJ, Lee HJ, Rockenstein E, Ho DH, Park EB, Yang NY, Desplats P, Masliah E, Lee SJ. J Neurosci. 2012 Sep 26;32(39):13454-69. PMID: 23015436
    14. a-Synuclein induces alterations in adult neurogenesis in Parkinson disease models via p53-mediated repression of Notch1. Desplats P, Spencer B, Crews L, Pathel P, Morvinski-Friedmann D, Kosberg K, Roberts S, Patrick C, Winner B, Winkler J, Masliah E. J Biol Chem. 2012 Sep 14;287(38):31691-702. PMID: 22833673
    15. Cell-to-cell transmission of a-synuclein aggregates. Lee SJ, Desplats P, Lee HJ, Spencer B, Masliah E. Methods Mol Biol. 2012;849:347-59. PMID: 22528101
    16. Forkhead box protein p1 is a transcriptional repressor of immune signaling in the CNS: implications for transcriptional dysregulation in Huntington disease. Tang B, Becanovic K, Desplats PA, Spencer B, Hill AM, Connolly C, Masliah E, Leavitt BR, Thomas EA. Hum Mol Genet. 2012 Jul 15;21(14):3097-111. PMID: 22492998
    17. Increased CDK5 expression in HIV encephalitis contributes to neurodegeneration via tau phosphorylation and is reversed with Roscovitine. Patrick C, Crews L, Desplats P, Dumaop W, Rockenstein E, Achim CL, Everall IP, Masliah E. Am J Pathol. 2011 Apr;178(4):1646-61. PMID: 21435449
    18. In vivo demonstration that alpha-synuclein oligomers are toxic. Winner B, Jappelli R, Maji SK, Desplats PA, Boyer L, Aigner S, Hetzer C, Loher T, Vilar M, Campioni S, Tzitzilonis C, Soragni A, Jessberger S, Mira H, Consiglio A, Pham E, Masliah E, Gage FH, Riek R. Proc Natl Acad Sci U S A. 2011 Mar 8;108(10):4194-9. PMID: 21325059
    19. Alpha-synuclein sequesters Dnmt1 from the nucleus: a novel mechanism for epigenetic alterations in Lewy body diseases. Desplats P, Spencer B, Coffee E, Patel P, Michael S, Patrick C, Adame A, Rockenstein E, Masliah E. J Biol Chem. 2011 Mar 18;286(11):9031-7. PMID: 21296890
    20. Cell-to-cell transmission of non-prion protein aggregates. Lee SJ, Desplats P, Sigurdson C, Tsigelny I, Masliah E. Nat Rev Neurol. 2010 Dec;6(12):702-6. PMID: 21045796
    21. Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy. Crews L, Spencer B, Desplats P, Patrick C, Paulino A, Rockenstein E, Hansen L, Adame A, Galasko D, Masliah E. PLoS One. 2010 Feb 19;5(2):e9313. PMID: 20174468
    22. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Desplats P, Lee HJ, Bae EJ, Patrick C, Rockenstein E, Crews L, Spencer B, Masliah E, Lee SJ. Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):13010-5. PMID: 19651612
    23. Dopamine receptor activation promotes adult neurogenesis in an acute Parkinson model. Winner B, Desplats P, Hagl C, Klucken J, Aigner R, Ploetz S, Laemke J, Karl A, Aigner L, Masliah E, Buerger E, Winkler J. Exp Neurol. 2009 Oct;219(2):543-52. PMID: 19619535
    24. The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice. Thomas EA, Coppola G, Desplats PA, Tang B, Soragni E, Burnett R, Gao F, Fitzgerald KM, Borok JF, Herman D, Geschwind DH, Gottesfeld JM. Proc Natl Acad Sci U S A. 2008 Oct 7;105(40):15564-9. PMID: 18829438
    25. Functional roles for the striatal-enriched transcription factor, Bcl11b, in the control of striatal gene expression and transcriptional dysregulation in Huntington's disease. Desplats PA, Lambert JR, Thomas EA. Neurobiol Dis. 2008 Sep;31(3):298-308. PMID: 18595722
    26. Alpha-synuclein alters Notch-1 expression and neurogenesis in mouse embryonic stem cells and in the hippocampus of transgenic mice. Crews L, Mizuno H, Desplats P, Rockenstein E, Adame A, Patrick C, Winner B, Winkler J, Masliah E. J Neurosci. 2008 Apr 16;28(16):4250-60. PMID: 18417705
    27. Glycolipid and ganglioside metabolism imbalances in Huntington's disease. Desplats PA, Denny CA, Kass KE, Gilmartin T, Head SR, Sutcliffe JG, Seyfried TN, Thomas EA. Neurobiol Dis. 2007 Sep;27(3):265-77. PMID: 17600724
    28. Selective deficits in the expression of striatal-enriched mRNAs in Huntington's disease. Desplats PA, Kass KE, Gilmartin T, Stanwood GD, Woodward EL, Head SR, Sutcliffe JG, Thomas EA. J Neurochem. 2006 Feb;96(3):743-57. PMID: 16405510